The Cancer Society is concerned about the lack of funding in this year's budget for new cancer drugs as the government juggles the unexpected spending on Covid-19.
Pharmac is getting an extra $160 million over four years to secure approved medicines.
The drug buying agency has already said the rising cost of medicines and extra freight expenses due to the pandemic, means funding for the likes of Keytruda for lung cancer, will have to be put on hold.
Chris Jackson is the medical director of the Cancer Society.
He speaks to Corin Dann.
